Polymersomes with splenic avidity target red pulp myeloid cells for cancer immunotherapy
Source abstract
Abstract
Abstract Regulating innate immunity is an emerging approach to improve cancer immunotherapy. Such regulation requires engaging myeloid cells by delivering immunomodulatory compounds to hematopoietic organs, including the spleen. Here we present a polymersome-based nanocarrier with splenic avidity and propensity for red pulp myeloid cell uptake. We characterized the in vivo behaviour of four chemically identical yet topologically different polymersomes by in vivo positron emission tomography imaging and innovative flow and mass cytometry techniques. Upon intravenous administration, relatively large and spherical polymersomes accumulated rapidly in the spleen and efficiently targeted myeloid cells in the splenic red pulp. When loaded with β-glucan, intravenously administered polymersomes significantly reduced tumour growth in a mouse melanoma model. We initiated our nanotherapeutic’s clinical translation with a biodistribution study in non-human primates, which revealed that the platform’s splenic avidity is preserved across species.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Immune cells in cancer · Immune responses and vaccinations
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (49)
Show source-provided references
1. Theobald, M. (ed). Current Immunotherapeutic Strategies in Cancer (Springer, 2020).10.1007/978-3-030-23765-3 ↗
2. Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838–857 (2021).10.1158/2159-8290.CD-20-1680 ↗
3. Engblom, C., Pfirschke, C. & Pittet, M. J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16, 447–462 (2016).10.1038/nrc.2016.54 ↗
4. Jung, K. et al. Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. J. Clin. Invest. 127, 3039–3051 (2017).10.1172/JCI93182 ↗
5. Kubli, S. P., Berger, T., Araujo, D. V., Siu, L. L. & Mak, T. W. Beyond immune checkpoint blockade: emerging immunological strategies. Nat. Rev. Drug Discov. 20, 899–919 (2021).10.1038/s41573-021-00155-y ↗
6. Wu, C. et al. Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. J. Clin. Invest. 128, 3425–3438 (2018).10.1172/JCI97973 ↗
7. Demaria, O. et al. Harnessing innate immunity in cancer therapy. Nature 574, 45–56 (2019).10.1038/s41586-019-1593-5 ↗
8. Priem, B. et al. Trained immunity-promoting nanobiologic therapy suppresses tumor growth and potentiates checkpoint inhibition. Cell 183, 786–801.e19 (2020).10.1016/j.cell.2020.09.059 ↗
9. Rabold, K. et al. Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma. Nat. Commun. 13, 6149 (2022).10.1038/s41467-022-33907-4 ↗
10. Lewis, S. M., Williams, A. & Eisenbarth, S. C. Structure and function of the immune system in the spleen. Sci. Immunol. 4, eaau6085 (2019).10.1126/sciimmunol.aau6085 ↗
11. Bronte, V. & Pittet, M. J. The spleen in local and systemic regulation of immunity. Immunity 39, 806–818 (2013).10.1016/j.immuni.2013.10.010 ↗
12. Swirski, F. K. et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325, 612–616 (2009).10.1126/science.1175202 ↗
13. Jordan, K. R. et al. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients. Cancer Immunol. Immunother. 66, 503–513 (2017).10.1007/s00262-016-1953-z ↗
14. Hiam-Galvez, K. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in cancer. Nat. Rev. Cancer 21, 345–359 (2021).10.1038/s41568-021-00347-z ↗
15. Wu, C., Hua, Q. & Zheng, L. Generation of myeloid cells in cancer: the spleen matters. Front. Immunol. 11, 1–13 (2020).10.3389/fimmu.2020.00001 ↗
16. Wang, X. & Li, Y. The disruption of hematopoiesis in tumor progression. Blood Sci. 1, 88–91 (2019).10.1097/BS9.0000000000000001 ↗
17. van der Meel, R. et al. Smart cancer nanomedicine. Nat. Nanotechnol. 14, 1007–1017 (2019).10.1038/s41565-019-0567-y ↗
18. Mulder, W. J. M., Ochando, J., Joosten, L. A. B., Fayad, Z. A. & Netea, M. G. Therapeutic targeting of trained immunity. Nat. Rev. Drug Discov. 18, 553–566 (2019).10.1038/s41573-019-0025-4 ↗
19. Bekkering, S. et al. In vitro experimental model of trained innate immunity in human primary monocytes. Clin. Vaccine Immunol. 23, 926–933 (2016).10.1128/CVI.00349-16 ↗
20. Bekkering, S. et al. Metabolic induction of trained immunity through the mevalonate pathway. Cell 172, 135–146.e9 (2018).10.1016/j.cell.2017.11.025 ↗
21. Arts, R. J. W. et al. Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metab. 24, 807–819 (2016).10.1016/j.cmet.2016.10.008 ↗
22. Domínguez-Andrés, J. et al. In vitro induction of trained immunity in adherent human monocytes. STAR Protoc. 2, 100365 (2021).10.1016/j.xpro.2021.100365 ↗
23. Netea, M. G. et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 20, 375–388 (2020).10.1038/s41577-020-0285-6 ↗
24. Kalafati, L. et al. Innate immune training of granulopoiesis promotes anti-tumor activity. Cell 183, 771–785.e12 (2020).10.1016/j.cell.2020.09.058 ↗
25. Geller, A. E. et al. The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Nat. Commun. 13, 759 (2022).10.1038/s41467-022-28407-4 ↗
26. Ding, C. et al. Inducing trained immunity in pro-metastatic macrophages to control tumor metastasis. Nat. Immunol. 24, 239–254 (2023).10.1038/s41590-022-01388-8 ↗
27. Mata-Martínez, P., Bergón-Gutiérrez, M. & del Fresno, C. Dectin-1 signaling update: new perspectives for trained immunity. Front. Immunol. 13, 1–18 (2022).10.3389/fimmu.2022.812148 ↗
28. Irvine, D. J. & Dane, E. L. Enhancing cancer immunotherapy with nanomedicine. Nat. Rev. Immunol. 20, 321–334 (2020).10.1038/s41577-019-0269-6 ↗
29. Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175–196 (2019).10.1038/s41573-018-0006-z ↗
30. Shi, Y. & Lammers, T. Combining nanomedicine and immunotherapy. Acc. Chem. Res. 52, 1543–1554 (2019).10.1021/acs.accounts.9b00148 ↗
31. van Leent, M. M. T. et al. A modular approach toward producing nanotherapeutics targeting the innate immune system. Sci. Adv. 7, 1–13 (2021).
32. Nam, J. et al. Cancer nanomedicine for combination cancer immunotherapy. Nat. Rev. Mater. 4, 398–414 (2019).10.1038/s41578-019-0108-1 ↗
33. Schudel, A. et al. Programmable multistage drug delivery to lymph nodes. Nat. Nanotechnol. 15, 491–499 (2020).10.1038/s41565-020-0679-4 ↗
34. Yi, S. et al. Surface engineered polymersomes for enhanced modulation of dendritic cells during cardiovascular immunotherapy. Adv. Funct. Mater. 29, 1904399 (2019).10.1002/adfm.201904399 ↗
35. Sofias, A. M., Combes, F., Koschmieder, S., Storm, G. & Lammers, T. A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system. Drug Discov. Today 26, 1482–1489 (2021).10.1016/j.drudis.2021.02.017 ↗
36. Lameijer, M. et al. Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. Nat. Biomed. Eng. 2, 279–292 (2018).10.1038/s41551-018-0221-2 ↗
37. Binderup, T. et al. Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species. Sci. Transl. Med. 11, eaaw7736 (2019).10.1126/scitranslmed.aaw7736 ↗
38. Scheerstra, J. F., Wauters, A. C., Tel, J., Abdelmohsen, L. K. E. A. & van Hest, J. C. M. Polymersomes as a potential platform for cancer immunotherapy. Mater. Today Adv. 13, 100203 (2022).10.1016/j.mtadv.2021.100203 ↗
39. Abdelmohsen, L. K. E. A. et al. Formation of well-defined, functional nanotubes via osmotically induced shape transformation of biodegradable polymersomes. J. Am. Chem. Soc. 138, 9353–9356 (2016).10.1021/jacs.6b03984 ↗
40. Wauters, A. C. et al. Development of morphologically discrete PEG-PDLLA nanotubes for precision nanomedicine. Biomacromolecules 20, 177–183 (2019).10.1021/acs.biomac.8b01245 ↗
41. Wibroe, P. P. et al. Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes. Nat. Nanotechnol. 12, 589–594 (2017).10.1038/nnano.2017.47 ↗
42. Yi, S. et al. Tailoring nanostructure morphology for enhanced targeting of dendritic cells in atherosclerosis. ACS Nano 10, 11290–11303 (2016).10.1021/acsnano.6b06451 ↗
43. Geng, Y. et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2, 249–255 (2007).10.1038/nnano.2007.70 ↗
44. Wauters, A. C. et al. Artificial antigen-presenting cell topology dictates T cell activation. ACS Nano 16, 15072–15085 (2022).10.1021/acsnano.2c06211 ↗
45. Pérez-Medina, C. et al. A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting. J. Nucl. Med. 55, 1706–1711 (2014).10.2967/jnumed.114.141861 ↗
46. Pérez-Medina, C., Teunissen, A. J. P., Kluza, E., Mulder, W. J. M. & van der Meel, R. Nuclear imaging approaches facilitating nanomedicine translation. Adv. Drug Deliv. Rev. 154–155, 123–141 (2020).10.1016/j.addr.2020.07.017 ↗
47. Song, K. et al. Laminarin promotes anti-cancer immunity by the maturation of dendritic cells. Oncotarget 8, 38554–38567 (2017).10.18632/oncotarget.16170 ↗
48. Carlino, M. S., Larkin, J. & Long, G. V. Immune checkpoint inhibitors in melanoma. Lancet 398, 1002–1014 (2021).10.1016/S0140-6736(21)01206-X ↗
49. Koo, B.-S. et al. Reference values of hematological and biochemical parameters in young-adult cynomolgus monkey (Macaca fascicularis) and rhesus monkey (Macaca mulatta) anesthetized with ketamine hydrochloride. Lab. Anim. Res. 35, 7 (2019).10.1186/s42826-019-0006-0 ↗